Zhongmeike Bio Secures Strategic Investment from Mori Capital to Advance Precision Skincare and Life Health Technologies

Recently, Chengdu Zhongmeike Biotechnology Co., Ltd. (hereinafter referred to as “Zhongmeike Biotech”), a brand specializing in at-home tech-enabled beauty devices, secured strategic investment from Senxi Capital.

According to Mr. Zhang Tao, Founder and CEO of Zhongmeike Biotechnology, Zhongmeike Biotechnology is a high-tech enterprise dedicated to research and development in the fields of life sciences and biotechnology. With a core R&D focus on skin health issues, the company has established capabilities in molecular biology, cell biology, IoT-enabled medical devices, and a big data information service platform for dermatology. It has secured more than 10 patents domestically and internationally, achieved multiple technology transfers, and established long-term, stable collaborative partnerships with major universities, hospitals, research institutions, and enterprises.

Deeply cultivating the niche sectors of life sciences and dermatological health, we integrate global high-end technological resources and achievements. Upholding a research ethos of integrity, rigor, pragmatism, and innovation, we are committed to building an integrated service platform encompassing R&D, technology, services, and sales. We provide scientifically formulated skincare solutions, anti-aging products, and precision medical-grade skincare devices to individuals with dermatological health concerns.

The company currently maintains long-term collaborations with numerous domestic and international biological laboratories and universities to conduct targeted research and development of biological products. With strong capabilities in biological products and medical technical services, the company provides customers with skincare product development and customized manufacturing services.

The company currently maintains long-term collaborations with numerous domestic and international biological laboratories and universities, conducting targeted product research and development for the medical aesthetics and health industries. It has established a comprehensive suite of services spanning biological medical aesthetic products as well as software and hardware technology development, thereby possessing high technical barriers and competitive advantages.

By leveraging a four-dimensional skin detection system that integrates RGB optical imaging, physical sensing, genetic testing, and microbiomics, and by employing precise big data algorithms, the physiological status of the skin is assessed to enable accurate analysis and diagnosis of dermatological issues.

Pioneering the innovative integration of medical devices and biotechnology in skin health management, this approach utilizes intelligent medical equipment to open skin channels, combined with bio-cellular applications, to achieve skin repair and regeneration. By constructing a multi-modular combination of hardware and software that effectively integrates microcurrent, ultrasound, light waves, and radiofrequency technologies, an IoT information platform for medical aesthetics is established.

Zhongmeike Biology is a Chinese company that designs, manufactures, and sells skincare devices. It began researching and developing its smart hydro-lifting instrument product line in 2018. After years of research and development, leveraging the expertise of dermatologists, molecular biologists, cell biologists, aestheticians, and mechanical engineers, the company provides high-quality solutions for diverse skincare and health needs.

MORI CAPITAL, the first institutional partner for early-stage entrepreneurs of Senxi Capital, is an emerging venture capital firm centered on a CVC investment model featuring MOM-selected managers. It focuses on technology-driven enterprises in the fields of intelligent manufacturing and consumer healthcare within the broader sci-tech innovation sector.